Research summary ·
PD-1/ PD-l1 Inhibitors and Stereotactic Radiosurgery for Brain Metastases: a systematic review and meta-analysis.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This study pooled results from earlier studies. It looked at people whose cancer had spread to the brain. All got radiation aimed at the brain spots, called SRS or FSRT. They also got drugs that block PD-1 or PD-L1. The team searched research databases up to November 2025. The studies came out between 2016 and 2025 and held 2,587 people.
What they found
The abstract gives a pooled survival rate at one year. It also gives separate survival rates for melanoma and lung cancer spread. It does not report a test of whether these rates differ. Control of the treated brain spots was high at one year. New spots elsewhere in the brain were held back less well. Grade 3 harm to brain tissue from radiation was not common. Severe nerve problems, grade 3 or worse, were also not common. The rate of tissue harm did not clearly differ between melanoma and lung cancer.
What it means for patients
The authors say radiation plus these drugs was linked to good control in the brain. They say the side effects seemed tolerable. In their view, severe radiation harm to brain tissue was fairly low. They feel these results show the combined approach is workable.
Why it is not certain yet
The authors say firm answers about extra risk of tissue harm need new trials. Such trials should follow people forward from the start. The pooled analysis looked at a single treated group, with no comparison group. A review can only be as good as the studies in it.
Source
PD-1/ PD-l1 Inhibitors and Stereotactic Radiosurgery for Brain Metastases: a systematic review and meta-analysis.
PubMed · PMID 42891757We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Brain metastases publications